FDA-cleared profile

Rayvolve PTX-PE

AZmed · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Clinical role
Passive study-level triage in PACS/DICOM workflow; it does not annotate the original image and is not a standalone clinical decision.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: The product is not a proactive specialist alert, does not annotate the original image, and is not intended as a standalone clinical decision or rule-out system.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Adult PA or AP chest X-rays received as DICOM studies; the FDA-described validation used 1,000 radiographs for pneumothorax and 1,000 for pleural effusion, with balanced positive and negative case groups.
  • Who uses it?Intended users: Radiologists and other qualified healthcare professionals reviewing adult chest radiographs.
  • What does the software produce?Output: A passive study-level header or secondary-capture result sent to PACS/DICOM node for worklist triage; no markup is placed on the original image.
  • What is its most important limitation?Key limitation: The product is not a proactive specialist alert, does not annotate the original image, and is not intended as a standalone clinical decision or rule-out system.

Clinical takeaway. Clinical role: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Evidence takeaway. Evidence from the reviewed source record: The FDA-described validation included 1,000 pneumothorax and 1,000 pleural-effusion radiographs. Pneumothorax sensitivity was 0.9379, specificity 0.9178 and AUC 0.9857. Pleural-effusion sensitivity was 0.9134, specificity 0.9448 and AUC 0.9830. Reported processing times were about 19.43 and 19.56 seconds respectively.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Passive study-level triage in PACS/DICOM workflow; it does not annotate the original image and is not a standalone clinical decision.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult PA or AP chest X-rays received as DICOM studies; the FDA-described validation used 1,000 radiographs for pneumothorax and 1,000 for pleural effusion, with balanced positive and negative case groups.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
A passive study-level header or secondary-capture result sent to PACS/DICOM node for worklist triage; no markup is placed on the original image.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Healthcare radiology services using adult PA or AP chest radiography.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists and other qualified healthcare professionals reviewing adult chest radiographs.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The product is not a proactive specialist alert, does not annotate the original image, and is not intended as a standalone clinical decision or rule-out system.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA-described validation included 1,000 pneumothorax and 1,000 pleural-effusion radiographs. Pneumothorax sensitivity was 0.9379, specificity 0.9178 and AUC 0.9857. Pleural-effusion sensitivity was 0.9134, specificity 0.9448 and AUC 0.9830. Reported processing times were about 19.43 and 19.56 seconds respectively.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA-described validation included 1,000 pneumothorax and 1,000 pleural-effusion radiographs. Pneumothorax sensitivity was 0.9379, specificity 0.9178 and AUC 0.9857. Pleural-effusion sensitivity was 0.9134, specificity 0.9448 and AUC 0.9830. Reported processing times were about 19.43 and 19.56 seconds respectively.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
0.9379 for pneumothorax; 0.9134 for pleural effusion
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Separate endpoints and populations; see evidence.metrics.

Reported specificity
0.9178 for pneumothorax; 0.9448 for pleural effusion
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Separate endpoints and populations; see evidence.metrics.

Pneumothorax sensitivity

0.9379 proportion

  • EndpointSensitivity
  • Population1,000 adult chest radiographs in the FDA pneumothorax validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Pneumothorax specificity

0.9178 proportion

  • EndpointSpecificity
  • Population1,000 adult chest radiographs in the FDA pneumothorax validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Pneumothorax AUC

0.9857 area under ROC curve

  • EndpointAUC
  • Population1,000 adult chest radiographs in the FDA pneumothorax validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Pleural-effusion sensitivity

0.9134 proportion

  • EndpointSensitivity
  • Population1,000 adult chest radiographs in the FDA pleural-effusion validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Pleural-effusion specificity

0.9448 proportion

  • EndpointSpecificity
  • Population1,000 adult chest radiographs in the FDA pleural-effusion validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Pleural-effusion AUC

0.983 area under ROC curve

  • EndpointAUC
  • Population1,000 adult chest radiographs in the FDA pleural-effusion validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Pneumothorax processing time

19.43 seconds

  • EndpointMedian or reported processing time as stated in the FDA summary
  • PopulationFDA pneumothorax validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Pleural-effusion processing time

19.56 seconds

  • EndpointMedian or reported processing time as stated in the FDA summary
  • PopulationFDA pleural-effusion validation set
  • Tested versionRayvolve PTX-PE configuration submitted in K243808

Rayvolve PTX-PE pneumothorax and pleural-effusion validation

  • DesignRetrospective standalone diagnostic performance validation described in the FDA 510(k) summary
  • PopulationTwo 1,000-radiograph adult chest X-ray sets, one for pneumothorax and one for pleural effusion
  • Scopeexact submission
  • Tested versionRayvolve PTX-PE configuration submitted in K243808
  • Samplen=2000
  • IndependenceSponsor or vendor study

K243808

The two disease endpoints use separate 1,000-study populations; results should not be treated as one pooled disease cohort.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult PA or AP chest X-rays received as DICOM studies; the FDA-described validation used 1,000 radiographs for pneumothorax and 1,000 for pleural effusion, with balanced positive and negative case groups.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243808: Rayvolve PTX-PE

  2. Routing

    Source context, not route validation: Study-level result is transmitted through a DICOM node/PACS workflow for passive worklist triage.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243808: Rayvolve PTX-PE

  3. AI processing

    Source context, not route validation: Standalone software connected to the radiology DICOM/PACS workflow; exact local hosting and routing terms are not specified in the public summary.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243808: Rayvolve PTX-PE

  4. Returned objects

    Source context, not route validation: A passive study-level header or secondary-capture result sent to PACS/DICOM node for worklist triage; no markup is placed on the original image.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243808: Rayvolve PTX-PE

  5. Viewer/worklist/report

    Unresolved route: A passive study-level header or secondary-capture result sent to PACS/DICOM node for worklist triage; no markup is placed on the original image.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243808: Rayvolve PTX-PE

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Standalone software connected to the radiology DICOM/PACS workflow; exact local hosting and routing terms are not specified in the public summary.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
Study-level result is transmitted through a DICOM node/PACS workflow for passive worklist triage.
  • Exact FDA submission
  • Checked 2026-09-07

Passive PACS worklist triage

The cleared output is a study-level header or secondary capture sent through a DICOM node/PACS workflow without markup on the original image.

exact submission · checked 2026-09-07

Rayvolve family workflow

AZmed presents Rayvolve as a radiology AI suite intended to fit clinical imaging workflows; the current page does not establish exact hosting, service levels or version for K243808.

product family · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243808
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for Rayvolve PTX-PE was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, per-study, subscription and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "AZmed Rayvolve reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    The reviewed sources do not establish exact-release security controls, retention or assurance documentation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K243808: Rayvolve PTX-PE

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, reportedSensitivity, reportedSpecificity, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rayvolve PTX-PE model card (K243808)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AI Radiology: Fracture Detection, Chest, Measure, BoneAge

    AZmed - Accessed 2026-09-06

    Scope: productFamilyContext, implementationCapabilities

Research history

  1. K243808 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K232410

SmartChest

Milvue

Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.

Modality
X-ray/Radiography
Anatomy
Chest/lung
Decision
2024-05-10
FDA-cleared K231871

Radify Triage

Envisionit DeepAI Ltd

Authorized purpose: Passively triage adult frontal chest X-rays for suspected pleural effusion and/or pneumothorax by providing case-level PACS worklist output; not a standalone clinical-decision tool or a rule-out result.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2024-01-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history